Canada’s MedC to Develop Cannabis-Based Cancer Treatment Based on Israeli Technology
MedC previously invested in the development of the treatments at Israel’s agricultural research organization, Volcani Center
11:5102.01.19
Cannabis treatment company MedC Biopharma Corporation of Canada announced earlier this month it has a global licensing agreement for a cannabis-based anti-cancer treatment developed at Israeli government research body Agricultural Research Organization (ARO), Volcani Center.
Medical cannabis. Photo: Getty Images
MedC, founded by Israeli brothers Avi and Guy Drori, also announced a partnership with a subsidiary of Israel-based Nextar Chempharma Solutions, an outsourcing company for drug development and manufacturing services, to develop treatments.
Volcani Center is preparing to submit the patents for the treatment of Cutaneous T cell lymphoma (CTCL), a type of immune system cancer that is classified by the U.S. Food and Drug Administration as an orphan disease. Clinical trials are planned for the beginning of 2019.
Medical cannabis. Photo: Getty Images
